Literature DB >> 33276038

Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.

Brittney H Davis1, Rajbeer Sangha2, Chrisly Dillon2, Todd M Brown3, Renuka Narayan2, Mark Beasley4, Tom McElderry3, Thomas D Nolin5, Nita A Limdi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33276038      PMCID： PMC8546791          DOI： 10.1053/j.ajkd.2020.09.018

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   11.072


× No keyword cloud information.
  8 in total

1.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions.

Authors:  Andrew S Levey; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2010-04       Impact factor: 8.860

Review 2.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2019-01-28       Impact factor: 29.690

Review 3.  Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019.

Authors:  Lane Zhang; David A Steckman; Evan C Adelstein; Joshua Schulman-Marcus; Alfred Loka; Roy O Mathew; Ferdinand J Venditti; Mandeep S Sidhu
Journal:  Cardiovasc Drugs Ther       Date:  2019-08       Impact factor: 3.727

4.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

5.  Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.

Authors:  Nita A Limdi; Thomas D Nolin; Sarah L Booth; Amanda Centi; Marisa B Marques; Michael R Crowley; Michael Allon; T Mark Beasley
Journal:  Am J Kidney Dis       Date:  2014-11-25       Impact factor: 8.860

6.  Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable.

Authors:  Jonathan P Piccini; Haolin Xu; Margueritte Cox; Roland A Matsouaka; Gregg C Fonarow; Javed Butler; Anne B Curtis; Nihar Desai; Margaret Fang; Pamela J McCabe; Robert L Page Ii; Mintu Turakhia; Andrea M Russo; Bradley P Knight; Mandeep Sidhu; Jodie L Hurwitz; Kenneth A Ellenbogen; William R Lewis
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

7.  Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study.

Authors:  Mohit A Limdi; Michael R Crowley; T Mark Beasley; Nita A Limdi; Michael Allon
Journal:  Am J Kidney Dis       Date:  2012-11-16       Impact factor: 8.860

8.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Mintu P Turakhia; Peter J Blankestijn; Juan-Jesus Carrero; Catherine M Clase; Rajat Deo; Charles A Herzog; Scott E Kasner; Rod S Passman; Roberto Pecoits-Filho; Holger Reinecke; Gautam R Shroff; Wojciech Zareba; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christoph Wanner
Journal:  Eur Heart J       Date:  2018-06-21       Impact factor: 29.983
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.